PLASMA-PROTEIN BINDING OF FENTANYL - THE EFFECT OF HYPERLIPOPROTEINEMIA AND CHRONIC-RENAL-FAILURE

[1] ANDREASEN F, 1973, ACTA PHARMACOL TOX, V32, P417

[2] ANDREASEN F, 1974, ACTA PHARMACOL TOX, V34, P284

[3] ANTON AH, 1971, ACTA PHARM TOXICOL S, V3, P134

[4] BOOBIS SW, 1977, CLIN PHARMACOL THER, V22, P147

[5] PLASMA-PROTEIN BINDING OF FENTANYL [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1981, 33 (08) : 507 - 514

[6] BOWER S, 1976, BRIT J ANAESTH, V48, P1121

[7] DANON A, 1979, CLIN PHARMACOL THER, V25, P316

[8] HATCH FT, 1968, ADV LIPID RES, V6, P2, DOI 10.1016/B978-1-4831-9942-9.50008-5

[9] DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM [J]. JOURNAL OF CLINICAL INVESTIGATION, 1955, 34 (09) : 1345 - 1353

[10] LOSOWSKY MS, 1968, J LAB CLIN MED, V71, P736

[1] ANDREASEN F, 1973, ACTA PHARMACOL TOX, V32, P417

[2] ANDREASEN F, 1974, ACTA PHARMACOL TOX, V34, P284

[3] ANTON AH, 1971, ACTA PHARM TOXICOL S, V3, P134

[4] BOOBIS SW, 1977, CLIN PHARMACOL THER, V22, P147

[5] PLASMA-PROTEIN BINDING OF FENTANYL [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1981, 33 (08) : 507 - 514

[6] BOWER S, 1976, BRIT J ANAESTH, V48, P1121

[7] DANON A, 1979, CLIN PHARMACOL THER, V25, P316

[8] HATCH FT, 1968, ADV LIPID RES, V6, P2, DOI 10.1016/B978-1-4831-9942-9.50008-5

[9] DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM [J]. JOURNAL OF CLINICAL INVESTIGATION, 1955, 34 (09) : 1345 - 1353

[10] LOSOWSKY MS, 1968, J LAB CLIN MED, V71, P736